Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 1
1995 1
1996 1
1997 2
1998 4
2000 1
2008 1
2014 1
2018 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.
Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ. Sano M, et al. N Engl J Med. 1997 Apr 24;336(17):1216-22. doi: 10.1056/NEJM199704243361704. N Engl J Med. 1997. PMID: 9110909 Free article. Clinical Trial.
BACKGROUND: There is evidence that medications or vitamins that increase the levels of brain catecholamines and protect against oxidative damage may reduce the neuronal damage and slow the progression of Alzheimer's disease. METHODS: We conducted a double-bli …
BACKGROUND: There is evidence that medications or vitamins that increase the levels of brain catecholamines and protect against oxidative da …
The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
LeWitt P, Oakes D, Cui L. LeWitt P, et al. Mov Disord. 1997 Mar;12(2):183-9. doi: 10.1002/mds.870120208. Mov Disord. 1997. PMID: 9087976 Clinical Trial.
Progression of Parkinson's disease (PD) can be detected through changes in clinical ratings or disability assessments. A clinical trial, Deprenyl and Alpha-Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP), used a novel st …
Progression of Parkinson's disease (PD) can be detected through changes in clinical ratings or disability assessments. A cl …
Rationale and design of a multicenter study of selegiline and alpha-tocopherol in the treatment of Alzheimer disease using novel clinical outcomes. Alzheimer's Disease Cooperative Study.
Sano M, Ernesto C, Klauber MR, Schafer K, Woodbury P, Thomas R, Grundman M, Growdon J, Thal LJ. Sano M, et al. Alzheimer Dis Assoc Disord. 1996 Fall;10(3):132-40. doi: 10.1097/00002093-199601030-00004. Alzheimer Dis Assoc Disord. 1996. PMID: 8876776 Clinical Trial.
This report describes the rationale and design of a clinical trial using selegiline (10 mg/day) and alpha-tocopherol (2,000 IU/day) to slow the progression of dementia in Alzheimer disease (AD). This study was developed by the A …
This report describes the rationale and design of a clinical trial using selegiline (10 mg/day) and alpha-toc …
Vitamin E and Alzheimer disease: the basis for additional clinical trials.
Grundman M. Grundman M. Am J Clin Nutr. 2000 Feb;71(2):630S-636S. doi: 10.1093/ajcn/71.2.630s. Am J Clin Nutr. 2000. PMID: 10681271 Review.
Vitamin E prevents the oxidative damage induced by beta-amyloid in cell culture and delays memory deficits in animal models. A placebo-controlled, clinical trial of vitamin E in patients with moderately advanced Alzheimer disease was conducted b …
Vitamin E prevents the oxidative damage induced by beta-amyloid in cell culture and delays memory deficits in animal models. A placebo-co …
DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism.
Shoulson I. Shoulson I. Ann Neurol. 1998 Sep;44(3 Suppl 1):S160-6. Ann Neurol. 1998. PMID: 9749589 Review.
In 1987, the DATATOP clinical trial was initiated to examine the benefits of deprenyl (selegiline) and alpha-tocopherol in slowing the progression of Parkinson's disease (PD). ...There were no accompanying benefits of deprenyl in postponi …
In 1987, the DATATOP clinical trial was initiated to examine the benefits of deprenyl (selegiline) and alpha- …
Current pharmacotherapies for Alzheimer's disease.
Knopman DS. Knopman DS. Geriatrics. 1998 Sep;53 Suppl 1:S31-4. Geriatrics. 1998. PMID: 9745634 Review.
This brief overview will describe some of the current anti-Alzheimer's disease (AD) agents. The relevance of the cholinergic deficit in AD is well-established. ...The success of alpha-tocopherol and selegiline in a recently conducted 2-ye …
This brief overview will describe some of the current anti-Alzheimer's disease (AD) agents. The relevance of the cholin …
Neuroprotection by anti-oxidant strategies in Parkinson's disease.
LeWitt PA. LeWitt PA. Eur Neurol. 1993;33 Suppl 1:24-30. doi: 10.1159/000118534. Eur Neurol. 1993. PMID: 8375428 Review.
Several recent studies have tested whether deprenyl (selegiline) or alpha-tocopherol (vitamin E) might attenuate the progression of Parkinson's disease. ...In the DATATOP trial, no neuroprotection was achieved with alpha-tocopherol …
Several recent studies have tested whether deprenyl (selegiline) or alpha-tocopherol (vitamin E) might attenuate the pr …
Vitamin B12 and Homocysteine Levels Predict Different Outcomes in Early Parkinson's Disease.
Christine CW, Auinger P, Joslin A, Yelpaala Y, Green R; Parkinson Study Group-DATATOP Investigators. Christine CW, et al. Mov Disord. 2018 May;33(5):762-770. doi: 10.1002/mds.27301. Epub 2018 Mar 6. Mov Disord. 2018. PMID: 29508904 Clinical Trial.
BACKGROUND: In moderately advanced Parkinson's disease (PD), low serum vitamin B12 levels are common and are associated with neuropathy and cognitive impairment. ...OBJECTIVE: To determine the prevalence of low vitamin B12 status in early PD and whether it is associated wi …
BACKGROUND: In moderately advanced Parkinson's disease (PD), low serum vitamin B12 levels are common and are associated with neuropat …
Pharmacologic approaches to cognitive deficits in Alzheimer's disease.
Peskind ER. Peskind ER. J Clin Psychiatry. 1998;59 Suppl 9:22-7. J Clin Psychiatry. 1998. PMID: 9720483 Review.
Two cholinesterase inhibitors are available for Alzheimer's disease, and others most likely will soon be available. Cholinesterase inhibitors represent the only therapy currently approved for the treatment of Alzheimer's disease …
Two cholinesterase inhibitors are available for Alzheimer's disease, and others most likely will soon be available. Cho …
Cerebrospinal fluid alpha-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort.
Stewart T, Liu C, Ginghina C, Cain KC, Auinger P, Cholerton B, Shi M, Zhang J; Parkinson Study Group DATATOP Investigators. Stewart T, et al. Am J Pathol. 2014 Apr;184(4):966-975. doi: 10.1016/j.ajpath.2013.12.007. Epub 2014 Mar 11. Am J Pathol. 2014. PMID: 24625392 Free PMC article. Clinical Trial.
We examined clinical data and alpha-synuclein in >300 unmedicated patients with PD who participated in the deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP) study, with up to 8 years of follow-up. Longitudinal measures of motor …
We examined clinical data and alpha-synuclein in >300 unmedicated patients with PD who participated in the deprenyl and …
14 results